Arrowhead Pharmaceuticals (ARWR) Rating Reiterated by Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reissued by research analysts at Chardan Capital in a report issued on Monday. They presently have a $24.50 price objective on the biotechnology company’s stock. Chardan Capital’s price target suggests a potential upside of 49.57% from the stock’s previous close.

A number of other research firms have also recently issued reports on ARWR. William Blair reaffirmed an “outperform” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 17th. Cantor Fitzgerald set a $24.00 price target on shares of Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 11th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Arrowhead Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $21.36.

Shares of NASDAQ ARWR traded up $0.72 during midday trading on Monday, reaching $16.38. 39,081 shares of the company’s stock traded hands, compared to its average volume of 1,510,907. Arrowhead Pharmaceuticals has a one year low of $4.77 and a one year high of $22.39. The company has a market cap of $1.45 billion, a PE ratio of -25.15 and a beta of 2.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, February 7th. The biotechnology company reported $0.13 EPS for the quarter, missing the Zacks’ consensus estimate of $0.76 by ($0.63). Arrowhead Pharmaceuticals had a negative net margin of 61.78% and a negative return on equity of 24.23%. The firm had revenue of $34.66 million for the quarter, compared to analysts’ expectations of $90.88 million. As a group, equities research analysts expect that Arrowhead Pharmaceuticals will post 1.49 earnings per share for the current year.

In related news, COO Bruce D. Given sold 42,666 shares of the firm’s stock in a transaction on Monday, January 14th. The shares were sold at an average price of $14.40, for a total transaction of $614,390.40. Following the completion of the transaction, the chief operating officer now owns 1,110,022 shares of the company’s stock, valued at $15,984,316.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $11.98, for a total transaction of $239,600.00. Following the transaction, the chief operating officer now directly owns 1,118,356 shares of the company’s stock, valued at approximately $13,397,904.88. The disclosure for this sale can be found here. In the last three months, insiders have sold 683,374 shares of company stock valued at $9,539,991. 4.80% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $52,000. Stratos Wealth Partners LTD. acquired a new stake in Arrowhead Pharmaceuticals during the third quarter valued at $123,000. Wealth Architects LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $124,000. Beaumont Financial Partners LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $124,000. Finally, Meeder Asset Management Inc. acquired a new stake in Arrowhead Pharmaceuticals during the third quarter valued at $129,000. Institutional investors own 59.52% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

See Also: How liquidity affects the bid-ask spread

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply